These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15516061)

  • 1. [Use of antipsychotics in first line].
    Stefos G
    Rev Med Brux; 2004 Sep; 25(4):A302-7. PubMed ID: 15516061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new antipsychotics. How much better are they?
    Keks N; Mazumdar P; Steele K
    Aust Fam Physician; 2000 May; 29(5):445-50. PubMed ID: 10835782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influences of second generation antipsychotics on the course of schizophrenia].
    Messer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S161-3. PubMed ID: 15570540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extrapyramidal effects of antipsychotic drugs].
    Kulisevsky J; Otermin P
    Neurologia; 2003 Jun; 18(5):262-8. PubMed ID: 12768512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composition and effects of commonly used neuroleptics.
    Culshaw F
    Nurs Times; 1994 Sep 21-27; 90(38):38-40. PubMed ID: 7971331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.
    Karow A; Schnedler D; Naber D
    Pharmacopsychiatry; 2006 Mar; 39(2):47-51. PubMed ID: 16555164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
    Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C
    Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [25 years antipsychotics: back to the future?].
    Denys D; de Haan L
    Tijdschr Psychiatr; 2008; 50 Spec no.():105-9. PubMed ID: 19067308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.